Stock Price Quote

MANAV PHARMA LTD.

NSE : NABSE : 524390ISIN CODE : Industry : Pharmaceuticals & DrugsHouse : Private
BSE0.000 (0 %)
PREV CLOSE ( ) NA
OPEN PRICE ( ) 0.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 0
TODAY'S LOW / HIGH ( )0.00 0.00
52 WK LOW / HIGH ( ) 00
NSE
This Company is not listed in NSE
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 1992
Management Info
- Chairman - Managing Director
Registered Office

Address Nirman House, 1St Floor, Near Sardar Vallabhbhai Patel Railway Crossing Usmanpura,
Ahmedabad,
Gujarat-380013

Phone

Email --

Website NA

Registrars Details
Manav Pharma Ltd.
Nirman House, 1St Floor, Near Sardar Vallabhbhai Patel Railway Crossing Usmanpura,Ahmedabad
Listing : BSE

NEWS

No News Found

Financials

in Millions
QTR ANNUAL
Net Profit
Gross Profit
Operating Profit
Net Sales

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Dr. Reddy's Lab (BSE)
peergroup  6445.00 (1.27%)
M.Cap ( in Cr)107511.08
Orchid Pharma (BSE)
peergroup  1217.20 (5.76%)
M.Cap ( in Cr)6173.53
Lincoln Pharma (BSE)
peergroup  737.20 (8.43%)
M.Cap ( in Cr)1476.59
Concord Biotech (BSE)
peergroup  1474.60 (2.39%)
M.Cap ( in Cr)15426.71
Mercury Laboratories (BSE)
peergroup  919.70 (3.87%)
M.Cap ( in Cr)110.36

Shareholding Pattern

No Data Found

About

no data found

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.